The INFUSE-Morphine IIB Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneous Morphine in Healthy Volunteers

Journal of Pain and Symptom Management

Volumn 38, Issue 5, 2009, Pages 673-682

  Thomas, Jay R ^a   Yocum, Richard C ^b   Haller, Michael F ^c   Flament, Jocelyne ^d  

^a City of Hope ^*  (United States)

^b Rockwell Medical Technologies Inc   (United States)

^c Halozyme Therapeutics Inc   (United States)

^d EORTC DATA CENTER   (Belgium)

Author keywords

difficult venous access; hospice; interstitial; morphine; pain; palliative care; parenteral; pharmacokinetics; Recombinant human hyaluronidase; subcutaneous

Indexed keywords

HYLENEX; MORPHINE; MORPHINE 6 GLUCURONIDE; PLACEBO; RECOMBINANT ENZYME; RECOMBINANT HUMAN HYALURONIDASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EYE PAIN; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; INJECTION SITE CONTUSION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL STIFFNESS; NAUSEA; NORMAL HUMAN; PALLOR; PARESTHESIA; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SENSATION OF HEAVINESS; SENSORY DYSFUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN;

ADULT; AGED; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MORPHINE; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 70350584815     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.03.010     Document Type: Article

References (20)

1. Bruera E., Legris M.A., Kuehn N., and Miller M.J. Hypodermoclysis for the administration of fluids and narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 5 (1990) 218-220
2. Hussain N.A., and Warshaw G. Utility of clysis for hydration in nursing home residents. J Am Geriatr Soc 44 (1996) 969-973
3. Frost G.I. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4 (2007) 427-440
4. Elsner F., Radbruch L., Loick G., Gartner J., and Sabatowski R. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. J Palliat Med 8 (2005) 743-750
5. Koshy R.C., Kuriakose R., Sebastian P., and Koshy C. Continuous morphine infusions for cancer pain in resource-scarce environments: comparison of the subcutaneous and intravenous routes of administration. J Pain Palliat Care Pharmacother 19 (2005) 27-33
6. Nelson K.A., Glare P.A., Walsh D., and Groh E.S. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage 13 (1997) 262-267
7. Bruera E., Fainsinger R., Spachynski K., et al. Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. J Clin Pharmacol 35 (1995) 666-672
8. Grune F., Schrappe M., Basten J., et al. Phlebitis rate and time kinetics of short peripheral intravenous catheters. Infection 32 (2004) 30-32
9. Kurul S., Saip P., and Aydin T. Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol 3 (2002) 684-692
10. Monreal M., and Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol 106 (2001) 69-72
11. Sasson M., and Shvartzman P. Hypodermoclysis: an alternative infusion technique. Am Fam Physician 64 (2001) 1575-1578
12. Bookbinder L.H., Hofer A., Haller M.F., et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114 (2006) 230-241
13. Yocum R.C., Kennard D., and Heiner L.S. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs 30 (2007) 293-299
14. Thomas J.R., Yocum R.C., Haller M.F., and von Gunten C.F. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med 10 (2007) 1312-1320
15. Pirrello R.D., Ting Chen C., and Thomas S.H. Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliat Med 10 (2007) 861-864
16. Stuart-Harris R., Joel S.P., McDonald P., Currow D., and Slevin M.L. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol 49 (2000) 207-214
17. Morsman C.D., and Holden R. The effects of adrenaline, hyaluronidase and age on peribulbar anaesthesia. Eye 6 Pt 3 (1992) 290-292
18. Roberts J.E., MacLeod B.A., and Hollands R.H. Improved peribulbar anaesthesia with alkalinization and hyaluronidase. Can J Anaesth 40 (1993) 835-838
19. Sarvela J., and Nikki P. Hyaluronidase improves regional ophthalmic anaesthesia with etidocaine. Can J Anaesth 39 (1992) 920-924
20. Nathan N., Benrhaiem M., Lotfi H., et al. The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. Anesth Analg 82 (1996) 1060-1064